Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
100 pending office actions • 48 clients • 93 examiners • 47 art units • 0 of 100 (0%) have an AI response strategy ready
BOZICEVIC, FIELD & FRANCIS LLP is heavily involved in the Biotechnology & Pharmaceuticals technology area. The firm has managed a significant career total of 8759 applications. There are 75 pending office actions currently being prosecuted.
The firm's resolved allowance rate is 75.76 percent. This is achieved with an average of 3.96 office actions per allowance. This average reflects the challenging nature of biotechnology and pharmaceutical prosecution, which often requires multiple rounds of negotiation with the USPTO. The 75.76 percent allowance rate provides a realistic expectation for success in these complex fields. With 75 pending actions, the firm has a substantial active docket. Practitioners can interpret the 3.96 average office actions as an indicator of the persistence required to navigate the examination process. The 8759 career applications highlight the firm's extensive experience in the life sciences sector.
Based on the USPTO statutory response window for each pending office action. 27 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 27 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 7 (7%) |
| §103 only | 16 (16%) |
| §102 only | 6 (6%) |
| §112 only | 8 (8%) |
| Double-patenting only | 1 (1%) |
| Double-patenting + other | 20 (20%) |
| Multi-statute (no §101) | 39 (39%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 2 | 64.8% | +55.2% |
| SCHLIENTZ, LEAH H | 2 | 41.9% | +38.5% |
| ZOU, NIANXIANG | 2 | 64.1% | +24.8% |
| ESSEX, LAURA ANN | 2 | 60.5% | +35.2% |
| MCCORMICK, CATHERINE LYNN | 2 | 50.0% | +42.5% |
| ENGLISH, CONNOR KENNEDY | 2 | 60.0% | +51.3% |
| RYAN, DOUGLAS CHARLES | 2 | 39.2% | +47.6% |
| LAMPRECHT, JOEL | 1 | 81.4% | +16.8% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.3% | +40.2% |
| CABRAL, ROBERT S | 1 | 62.6% | +32.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19202992 | Methods for Biomedical Targeting and Delivery and Devices and Systems for Practicing the Same | LAMPRECHT, JOEL | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036133 | CLUBROOT RESISTANCE IN RAPESEED BRASSICA NAPUS | WILLIAMS, KEITH RICHARD | 210d overdue |
| 18863312 | Nanoparticles for Delivery of Nucleic Acid Cargos | SCHLIENTZ, LEAH H | 25d overdue |
| 18265410 | Plants With Sr2-mediated Stem Rust Resistance | ORDAZ, CHRISTIAN JOSE | 4d overdue |
| 18702756 | Wearable Non-Invasive Central Nervous System Neuromodulator and Methods for Using Same | KOWALKOWSKI, FIONA MARGARET | 2d overdue |
| 18034045 | CONTROLLING CELLULAR BEHAVIOR USING FEED-FORWARD CIRCUITS | NICOL, ALEXANDER W | 19d |
| 18551502 | Pharmaceutical Combinations for Treating Cancer | BUTTICE, AUDREY L | 42d |
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | NIEBAUER, RONALD T | 60d |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | SKELDING, ZACHARY S | 63d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17630875 | SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 74d overdue |
| 18863312 | Nanoparticles for Delivery of Nucleic Acid Cargos | SCHLIENTZ, LEAH H | 25d overdue |
| 19054584 | Linear DNA with Enhanced Resistance Against Exonucleases | DACE DENITO, ALEXANDRA GERALDINE | 3d overdue |
| 17773404 | MrgprX2 Antagonists and Uses Thereof | ENGLISH, CONNOR KENNEDY | 7d |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | RYAN, DOUGLAS CHARLES | 12d |
| 17769693 | NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS, METHODS OF USE AND METHODS OF MAKING THEREOF | SCHLIENTZ, LEAH H | 23d |
| 18039840 | Antibody Delivery | MCCORMICK, CATHERINE LYNN | 26d |
| 19540475 | Immunoassays for Buprenorphine and Metabolites | HAQ, SHAFIQUL | — |
| Art Unit | Apps |
|---|---|
| 3792 | 4 |
| 1671 | 4 |
| 1654 | 3 |
| 1672 | 3 |
| 3791 | 3 |
| 1675 | 3 |
| 1678 | 2 |
| 3798 | 2 |
| 1618 | 2 |
| 1617 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19540475 | Immunoassays for Buprenorphine and Metabolites | Ark Diagnostics, Inc. | HAQ, SHAFIQUL | 1678 | §103§112 | Final Rejection | — | Pending | Feb 13, 2026 |
| 19202992 | Methods for Biomedical Targeting and Delivery and Devices and Systems for Practicing the Same | The Regents of the University of California | LAMPRECHT, JOEL | 3798 | §102§103§112DP | Non-Final OA | — | Pending | May 08, 2025 |
| 19054584 | Linear DNA with Enhanced Resistance Against Exonucleases | 4Basebio UK Ltd. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103DP | Final Rejection | 3d overdue | Pending | Feb 14, 2025 |
| 18942149 | Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding | Samson Clinical Pty Ltd. | CABRAL, ROBERT S | §103 | Non-Final OA | — | Pending | Nov 08, 2024 | |
| 18863312 | Nanoparticles for Delivery of Nucleic Acid Cargos | 4Basebio UK Ltd. | SCHLIENTZ, LEAH H | 1618 | §102§103 | Non-Final OA | 25d overdue | Pending | Nov 05, 2024 |
| 18857803 | MESENCEPHALIC ASTROCYTE-DERIVED NEUROTROPHIC FACTOR (MANF) FOR INCREASING MUSCLE REGENERATION | Gulbenkian Institute For Molecular Medicine | CANDELARIA, JULIANA IRENE | §102§112 | Non-Final OA | — | Pending | Oct 17, 2024 | |
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | The Regents of the University of California | TIWARI, VYOMA SHUBHAM | §112 | Final Rejection | — | Pending | Oct 10, 2024 | |
| 18853680 | Delineation of One or More Parts of a Body Within a Diffusion Weighted MRI Image | Cancer Research Technology Ltd. | BLACKSTEN, SYDNEY LYNN | §101§103Other | Non-Final OA | — | Pending | Oct 02, 2024 | |
| 18903947 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112Other | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18843688 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | Immunophage Biotech (Shanghai) Co., Ltd. | ROCHELLE, CIERRA MARIE | §103§112 | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18727631 | Treatment of GM2 Gangliosidosis | Azafaros B.V. | RODRIGUEZ-GARCIA, VALERIE | §102§103§112DP | Non-Final OA | — | Pending | Jul 09, 2024 | |
| 18725112 | Application of Polypeptide in Preparation of Product for Preventing or Treating Skin Injury Diseases | Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd. | KATAKAM, SUDHAKAR | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 | |
| 18719710 | NOVEL SALT OF 1-SULFONYL PYRROLE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Ildong Pharmaceutical Co., Ltd. | JAVANMARD, SAHAR | §102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18716761 | CLOSO-DODECAIODODECABORATE COMPLEXES AND METHODS OF USE FOR SAME | The Regents of the University of California | JONES, DAMERON LEVEST | §103§112 | Non-Final OA | — | Pending | Jun 05, 2024 | |
| 18716045 | An Automated Process for Optimizing Spinal Cord Stimulation | The Regents of the University of California | COLLARD JR, DWANE EDWARD | 3792 | §102§103§112 | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18672931 | Rust Resistance Gene | Commonwealth Scientific And Industrial Research Organisation | IBRAHIM, MEDINA AHMED | 1662 | Other | Final Rejection | 15d overdue | Pending | May 23, 2024 |
| 18658264 | Methods for Representing Data Analysis and Systems for Same | The Regents of the University of California | SILVERMAN, SETH ADAM | 2172 | §103 | Final Rejection | 12d | Pending | May 08, 2024 |
| 18657366 | Methods of Producing Size-Selected Nucleic Acid Libraries and Compositions and Kits for Practicing Same | The Regents of the University of California | BUNKER, AMY M | §103§112 | Non-Final OA | — | Pending | May 07, 2024 | |
| 18653683 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | ZOU, NIANXIANG | 1671 | §103§112DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18649688 | CRY PROTEIN CRYSTALS AND METHODS OF USE | BATTELLE MEMORIAL INSTITUTE | JOHNSON, TIRONE DEREK | §102§103 | Non-Final OA | — | Pending | Apr 29, 2024 | |
| 18703256 | Coxsackievirus B Compositions and Methods Of Use Thereof | Vactech OY | SIFFORD, JEFFREY MARK | §101§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 | |
| 18702756 | Wearable Non-Invasive Central Nervous System Neuromodulator and Methods for Using Same | Spinex Inc. | KOWALKOWSKI, FIONA MARGARET | 3792 | §102§103 | Non-Final OA | 2d overdue | Pending | Apr 18, 2024 |
| 18697402 | DEVICES FOR DETECTION OF NEUTROPHIL LEVEL | 52 North Health Ltd. | KRCHA, MATTHEW D | §102§103 | Non-Final OA | — | Pending | Mar 29, 2024 | |
| 18696922 | Anti-Human Astrovirus Antibodies and Related Compositions and Methods | Universidad Nacional Autónoma De México | NICKOL, GARY B | §102§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 | |
| 18690688 | Lithium Sulfur Cell | Cambridge Enterprise Limited | D'ANIELLO, NICHOLAS P | §102§112 | Non-Final OA | — | Pending | Mar 08, 2024 | |
| 18690533 | Suppression of Neurodegeneration with Zinc Transporter Protein 7 | The Regents of the University of California | CESARE, JOSEPH DAVID | §103§112 | Non-Final OA | — | Pending | Mar 08, 2024 | |
| 18688602 | STEROL THERAPY | Jena University Hospital | KIM, SEONG JONG | 1623 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18682740 | Vaccine Antigen | Macfarlane Burnet Institute For Medical Research And Public Health Limited | CHESTNUT, BARRY A | §102§112 | Non-Final OA | — | Pending | Feb 09, 2024 | |
| 18294487 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS | Wayne Stephen Andrews | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 39d | Pending | Feb 01, 2024 |
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | Vactech OY | CHEN, STACY BROWN | 1672 | §112 | Final Rejection | 11d overdue | Pending | Jan 19, 2024 |
| 18580417 | Methods and Model Systems for Assessing Therapeutic Properties of Candidate Agents and Related Computer Readable Media and Systems | The Regents of the University of California | BARRON, SEAN C | 1682 | §102§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579775 | A Surface Audio-Visual Biofeedback (SAVB) System for Motion Management | The Board Of Trustees Of The Leland Stanford Junior University | HON, MING Y | §103 | Non-Final OA | — | Pending | Jan 16, 2024 | |
| 18579291 | Microcapsules and Methods for Preparing Microcapsules | Cpl Aromas Limited | ALLEY, GENEVIEVE S | 1617 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18578617 | Compounds for Modulating Epithelial 15-(S)-Lipoxygenase-2 and Methods of Use for Same | The Regents of the University of California | KUCKLA, ANNA GRACE | 1626 | §103§112 | Final Rejection | — | Pending | Jan 11, 2024 |
| 18395150 | Vaccine Therapy | Ac Immune SA | FONTAINHAS, AURORA M | 1649 | DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18391501 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18544206 | Method of Neural Intervention for the Treatment of Affective Neuropsychiatric Disorders | The Regents of the University of California | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18570390 | Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods | The Regents of the University of California | KOMATSU, LI N | 1658 | §102§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18568243 | Treatment or Prevention of Ischaemia Reperfusion Injury | Cambridge Enterprise Limited | NEAGU, IRINA | 1629 | §103DP | Final Rejection | — | Pending | Dec 07, 2023 |
| 18529858 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | The Governors of the University of Alberta | JADHAO, SAMADHAN JAISING | 1672 | §103§112DP | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18523548 | Compounds and Methods for Use in Detecting Gabapentin | Ark Diagnostics, Inc. | HAQ, SHAFIQUL | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 | |
| 18565049 | Polymeric Antifouling Coating with Antimicrobial Peptides | The University of British Columbia | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18520057 | E1E2 HCV VACCINES AND METHODS OF USE | The Governors of the University of Alberta | ZOU, NIANXIANG | 1671 | §101§103Other | Final Rejection | — | Pending | Nov 27, 2023 |
| 18561981 | Methods And Devices For Real-Time Word And Speech Decoding From Neural Activity | The Regents of the University of California | PADDA, ARI SINGH KANE | 3791 | §101§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18288793 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18384266 | WATER DISPERSIBLE GRANULE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18382419 | SUSPENSION CONCENTRATE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103§112DP | Final Rejection | 113d overdue | Pending | Oct 20, 2023 |
| 18287604 | Thermally Stable Lipid-Nucleic Acid Molecule Formulations Utilising Metal Organic Framework (MOF) Shells | Commonwealth Scientific And Industrial Research Organisation | ARNOLD, ERNST V | 1613 | §103DP | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18287094 | Closed-Loop Neuromodulation for the Treatment of Affective Neuropsychiatric Disorders | The Regents of the University of California | MARLEN, TAMMIE K | 3792 | §103 | Final Rejection | — | Pending | Oct 16, 2023 |
| 18285814 | Thermally Stable Vaccine Formulations Utilising Metal Organic Framework (MOF) Shells | Commonwealth Scientific And Industrial Research Organisation | PARK, HAEJIN S | 1614 | §102 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18551502 | Pharmaceutical Combinations for Treating Cancer | T3 Pharmaceuticals AG | BUTTICE, AUDREY L | 1647 | §103§112Other | Non-Final OA | 42d | Pending | Sep 20, 2023 |
| 18468639 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | The Regents of the University of California | ESSEX, LAURA ANN | 1675 | §102§112Other | Final Rejection | — | Pending | Sep 15, 2023 |
| 18468633 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California | ESSEX, LAURA ANN | 1675 | §112DP | Final Rejection | — | Pending | Sep 15, 2023 |
| 18278719 | ASSEMBLED THREE-DIMENSIONAL CULTURES OF HUMAN NEURONS AND GLIA AND THEIR USE | The Regents of the University of California | TICHY, JENNIFER M.H. | 1653 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18547139 | Oncolytic Virus and Methods of Use | NorthShore University HealthSystem | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | — | Pending | Aug 18, 2023 |
| 18276834 | Endometriosis-Related Methods and Compositions | The Regents of the University of California | AL-AWADI, DANAH J | 1615 | §103 | Final Rejection | — | Pending | Aug 10, 2023 |
| 18276848 | RNA Trans-Splicing Molecule | Cambridge Enterprise Limited | TRAN, CHRISTINA L | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18275170 | Methods for Pulmonary Function Testing With Machine Learning Analysis and Systems for Same | The Regents of the University of California | HANEY, JONATHAN MICHAEL | 3791 | §101 | Final Rejection | — | Pending | Jul 31, 2023 |
| 18274152 | Genetically Modified Hepatocyte Populations | Cytotheryx, Inc. | YU, MISOOK | 1641 | §102§103§112 | Non-Final OA | 84d | Pending | Jul 25, 2023 |
| 18223943 | Drug Implants Containing Darolutamide and Methods of Use Thereof | Alessa Therapeutics, Inc. | WERTZ, ASHLEE ELIZABETH | 1612 | §103DP | Final Rejection | 58d overdue | Pending | Jul 19, 2023 |
| 18222436 | METHOD AND APPARATUS FOR REDUCING EXCESS PRESSURE IN ISOCHORIC SYSTEMS | Biochoric, Inc. | KOSAR, AARON J | 1655 | §102§103 | Non-Final OA | — | Pending | Jul 15, 2023 |
| 18351367 | Autoantigens Engineered to Suppress Autoimmune Response | Adaxion Therapeutics, Inc. | ALDARONDO, DASIA ALI | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18261083 | Linear DNA With Enhanced Resistance Against Exonucleases and Methods for the Production Thereof | 4Basebio UK Ltd. | SCHLOOP, ALLISON ELIZABETH | 1693 | §103DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd. | NIEBAUER, RONALD T | 1658 | §101§102§112 | Non-Final OA | 60d | Pending | Jul 10, 2023 |
| 18210515 | Magnesium Threonate Compositions and Uses Thereof | Neurocentria, Inc. | SOROUSH, LAYLA | 1622 | §103DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18208576 | METHOD AND APPARATUS FOR REDUCING PROBABILITY OF ICE NUCLEATION DURING PRESERVATION OF BIOLOGICAL MATTER IN ISOCHORIC SYSTEMS | Biochoric, Inc. | MCCORMICK, CATHERINE LYNN | 1638 | §102§103DP | Final Rejection | — | Pending | Jun 12, 2023 |
| 18265410 | Plants With Sr2-mediated Stem Rust Resistance | Grains Research And Development Corporation | ORDAZ, CHRISTIAN JOSE | 1663 | §102§112 | Non-Final OA | 4d overdue | Pending | Jun 05, 2023 |
| 18265171 | Biliary Delivery Methods, Compositions and Kits for Use Therein | Cytotheryx, Inc. | ROSENTHAL, ANDREW S | 1613 | §103 | Final Rejection | 61d | Pending | Jun 02, 2023 |
| 18039840 | Antibody Delivery | Ac Immune SA | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Final Rejection | 26d | Pending | Jun 01, 2023 |
| 18036133 | CLUBROOT RESISTANCE IN RAPESEED BRASSICA NAPUS | Npz Innovation GmbH | WILLIAMS, KEITH RICHARD | 1663 | §102§103 | Non-Final OA | 210d overdue | Pending | May 09, 2023 |
| 18034338 | NEW POLYMERASE AND USE THEREOF | Genovis AB | BOWERS, ERIN M | 1653 | §102§103§112 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18034045 | CONTROLLING CELLULAR BEHAVIOR USING FEED-FORWARD CIRCUITS | The Regents of the University of California | NICOL, ALEXANDER W | 1634 | §102§103§112 | Final Rejection | 19d | Pending | Apr 26, 2023 |
| 18032513 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | Andreas Gloger | LAFAVE, ELIZABETH ROSE | 1684 | §102 | Non-Final OA | — | Pending | Apr 18, 2023 |
| 18027292 | Devices and Methods for Evaluating the Viability of Embryos | The Regents of the University of California | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Final Rejection | — | Pending | Mar 20, 2023 |
| 18017849 | COMBINATORIAL ANTIGEN RECOGNITION IN CANCER T CELL THERAPIES | The Simons Foundation, Inc. | PETERS, ALEC JON | 1641 | §103§112DP | Final Rejection | 20d | Pending | Jan 24, 2023 |
| 18015309 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. | YOO, SUN JAE | 1621 | §102 | Final Rejection | 39d | Pending | Jan 09, 2023 |
| 17998641 | METHODS AND ANTIBODIES IN TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | The Regents of the University of California | SHUPE, ELIZABETH A | 1643 | §103Other | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17921739 | Methods for Generating Thymic Cells in Vitro | The Regents of the University of California | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17995058 | Methods, Compositions, and Kits for Identifying Regions of Genomic DNA Bound to a Protein | The Brigham And Women'S Hospital, Inc. | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103 | Non-Final OA | 53d overdue | Pending | Sep 29, 2022 |
| 17822584 | T CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | BLUMEL, BENJAMIN P | 1671 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17800516 | Inhibitors of Human Herpesviruses | The Governors of the University of Alberta | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | The Simons Foundation, Inc. | SKELDING, ZACHARY S | 1644 | §102§103 | Non-Final OA | 63d | Pending | Jun 23, 2022 |
| 17745399 | NANOPORE SENSOR FOR ENZYME-MEDIATED PROTEIN TRANSLOCATION | The Regents of the University of California | MINCHELLA, KAITLYN L | 1685 | §112DP | Final Rejection | — | Pending | May 16, 2022 |
| 17773404 | MrgprX2 Antagonists and Uses Thereof | Dermira, Inc. | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Final Rejection | 7d | Pending | Apr 29, 2022 |
| 17733866 | Method for Determining Relatedness of Genomic Samples Using Partial Sequence Information | The Regents of the University of California | WOITACH, JOSEPH T | 1631 | §101§103 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17769693 | NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS, METHODS OF USE AND METHODS OF MAKING THEREOF | Manzanita Pharmaceuticals, Inc. | SCHLIENTZ, LEAH H | 1618 | §102 | Final Rejection | 23d | Pending | Apr 15, 2022 |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | UVIC INDUSTRY PARTNERSHIPS INC. | PATTERSON, SARAH COOPER | 1675 | §112Other | Final Rejection | 46d | Pending | Mar 10, 2022 |
| 17633749 | Neurofeedback Training to Promote Sharp Wave Ripples | The Regents of the University of California | ORTEGA, MARTIN NATHAN | 3791 | §101 | Final Rejection | — | Pending | Feb 08, 2022 |
| 17630875 | SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF | The Regents of the University of California | RYAN, DOUGLAS CHARLES | 1635 | §103§112DP | Final Rejection | 74d overdue | Pending | Jan 27, 2022 |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | The Regents of the University of California | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 12d | Pending | Dec 07, 2021 |
| 17605198 | MODULATING SURVIVAL OF THERAPEUTIC CELLS AND METHODS, CELLS AND NUCLEIC ACIDS RELATED THERETO | The Regents of the University of California | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | — | Pending | Oct 20, 2021 |
| 17459160 | Vibratory Expulsive Therapy For Urinary Stones | The Regents of the University of California | LEDERER, SARAH B | 3785 | §103 | Non-Final OA | 49d overdue | Pending | Aug 27, 2021 |
| 17419234 | SYNTHETIC MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME | The Regents of the University of California | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Final Rejection | — | Pending | Jun 28, 2021 |
| 17316153 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | Adepthera LLC | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | May 10, 2021 |
| 17282319 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | The University of British Columbia | VAJDA, KRISTIN ANN | 1622 | §102 | Final Rejection | — | Pending | Apr 01, 2021 |
| 17275110 | Artificial Periosteum | Orthocell Limited | MARTINEZ, TARA L | 1654 | §103 | Final Rejection | — | Pending | Mar 10, 2021 |
| 17266911 | Monodispersed Particle-Triggered Droplet Formation from Stable Jets | The Regents of the University of California | THOMPSON, CURTIS A | 1798 | §103§112 | Final Rejection | — | Pending | Feb 08, 2021 |
| 17258403 | Multimodal Neuroimaging-Based Diagnostic Systems and Methods for Detecting Tinnitus | The Regents of the University of California | KELLOGG, MICHAEL S | 3798 | §112 | Final Rejection | — | Pending | Jan 06, 2021 |
| 17040476 | TRANS-ANTIGEN TARGETING IN HETEROGENEOUS CANCERS AND METHODS OF USE THEREOF | The Regents of the University of California | SZPERKA, MICHAEL EDWARD | 1600 | §103Other | Final Rejection | — | Pending | Sep 22, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial